Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive ...

Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that ...

Oliver Barnes Pfizer and Novo Nordisk duked it out for who will own Metsera — a coveted biotech that’s developing ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

The tussle between the two drugmakers has spread from the boardroom to the courtroom to the corridors of Washington ...

Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold ...

Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...